Ozempic and similar weight-loss shots are doing something doctors didn’t fully expect: changing how people experience desire, not just how they look in the mirror.
At a Glance
- New research shows GLP-1 drugs can raise or lower sex drive, depending on the patient
- Some large database studies link semaglutide to higher rates of erectile dysfunction and low testosterone
- Other clinical data show the same drug class improving erectile function and desire
- Scientists now suspect brain reward chemistry, not just weight loss, is driving the effect
- A Kinsey Institute survey found roughly half of users say the drugs changed their sex life, for better or worse
One Drug Class, Two Opposite Headlines
GLP-1 medications like Ozempic, Wegovy, and Mounjaro were built to treat diabetes and obesity. Nobody designed them to touch the bedroom. Yet patients keep reporting changes in desire, and researchers are racing to explain why the same drug seems to boost some people’s sex drive while flattening someone else’s. The honest answer right now is that both things appear to be true, depending on the person.
That split is not a reporting error. It shows up across multiple studies using different methods, different patient groups, and different versions of the drug. Understanding why requires looking at two competing bodies of evidence instead of picking one headline and running with it.
The Case That These Drugs Hurt Male Sexual Function
A widely cited TriNetX database study compared non-diabetic men prescribed semaglutide against matched men who were not. The semaglutide group was far more likely to be diagnosed with erectile dysfunction or prescribed a drug to treat it, and also more likely to develop low testosterone. Separate pharmacovigilance reports pulled from the Food and Drug Administration’s adverse event database found over 180 cases of male sexual dysfunction tied to GLP-1 drugs, including low libido and orgasm problems.
These are real signals worth taking seriously, but they come with a catch. Database studies like these track who got diagnosed or prescribed something, not what actually caused it. Men losing large amounts of weight see doctors more often, which alone can raise diagnosis rates without proving the drug itself broke anything.
The Case That These Drugs Help
A different line of research points the opposite direction. One clinical study found that GLP-1 receptor agonists produced a significant improvement in erectile function and sexual desire compared to how patients scored before treatment, and the testosterone gains showed up independent of how much weight patients actually lost. That detail matters. It suggests the drug may be acting directly on the body’s hormone control system, not simply rewarding patients for shedding pounds.
Other researchers have found something similar: rising testosterone in men with obesity or type 2 diabetes, alongside improved blood flow and body composition, the physical ingredients erectile function depends on. For men whose sexual problems started with excess weight and poor metabolic health, fixing the underlying disease appears to fix downstream performance too.
Why the Brain Might Be the Real Battleground
The more interesting theory involves wiring, not just hormones. GLP-1 receptors sit in brain regions tied to appetite and reward, and scientists believe turning down hunger signals may also turn down other reward-driven urges, sex included, for some users. That would explain why a drug built to quiet cravings for food might quietly quiet cravings for intimacy in certain people, even while it improves blood flow elsewhere in the body.
Not every analysis agrees the signal is even strong. One review of FAERS adverse event reports found the statistical link between GLP-1 drugs and male sexual dysfunction was weak once researchers accounted for how many total reports exist for any drug of this size and popularity. Men aged 40 to 60 made up most of the reported cases, an age group already prone to erectile issues regardless of medication.
What This Means for Patients Right Now
A Kinsey Institute survey found that roughly half of GLP-1 users reported changes to their sex life, and the results split almost evenly between improved and worsened desire, comfort with their bodies, and sexual function. That even split tells the real story better than any single study. These drugs do not have one sexual side effect. They have several, and which one a patient gets likely depends on their starting weight, hormone levels, mental health, and how their individual brain chemistry responds to appetite suppression.
Patients weighing these drugs should talk to their doctor about baseline testosterone and sexual function before starting, so any change afterward can be measured honestly instead of guessed at. Common sense says a medication this widely prescribed deserves rigorous, controlled research into this specific side effect, not just scattered database mining years after millions of Americans are already on it.
Sources:
menshealth.com, onlinelibrary.wiley.com, pmc.ncbi.nlm.nih.gov
